Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for Non-responsive Eosinophilic Esophagitis
NCT07588568Phase 2Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2026
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of upadacitinib in eosinophilic esophagitis (EoE), sponsored by University of North Carolina at Chapel Hill. Started Sep 2026; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT07588568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588568.